ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

suzetrigine

Also written as “Suzetrigine”, “VX-548” and “SUZ”.

Its studies are mostly in Pain · Acute Pain · Neuralgia · Radiculopathy, led by 2 companies.

Drug pageSuzetrigine: every studyAll 57 studies of it, academic ones too, with its approvals, label and forms.
Furthest: phase 4, since Mar 19, 202527 company-led studies, 3 open or runningNext primary completion: Jan 25, 2027 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Vertex Pharmaceuticalsits history only263 open or runningphase 4since Mar 19, 2025Jul 15, 2021Jan 25, 2027phase 3 · NCT06696443
Latigo Biotherapeutics10 open or runningearly phase 1since May 6, 2025May 6, 2025none ahead

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of Latigo Biotherapeutics only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.

  1. Jan 19, 2023Named suzetrigineINNProposed as its International Nonproprietary Name in WHO's List 128 · before, VX-548
  2. May 6, 2025First study: early phase 1 study in Pain DetectionFirst studyNCT06972212 · 20 enrolled · New Zealand

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

The one study Latigo Biotherapeutics leads. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT06972212Pain Detection · New ZealandEarly 1CompletedJun 28, 202520

How it is read

Names in the registry

  • “Suzetrigine”, 13 entries
  • “VX-548”, 11 entries
  • “SUZ”, 2 entries
  • “suzetrigine 100mg”, 1 entry
  • “Suzetrigine (SUZ)”, 1 entry

Codes read as this program: VX548.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.